Back to today’s briefing

Story perspectives

China's New Drug List Slashes Alzheimer’s Costs for Millions

12/17/2025

38 9

Summary

Story summary

Mainland China unveiled a commercial insurance innovative drug list that could cut out-of-pocket costs for 17 million Alzheimer’s patients.
Leqembi, priced about US$28,400 annually, could have its price halved under the scheme.
The list also includes Eli Lilly’s Kisunla, viewed as a significant Alzheimer’s advancement.
Final out-of-pocket costs will depend on negotiations between drug developers and Chinese insurance companies.

1 of 1

Story summary

Mainland China unveiled a commercial insurance innovative drug list that could cut out-of-pocket costs for 17 million Alzheimer’s patients.
Leqembi, priced about US$28,400 annually, could have its price halved under the scheme.
The list also includes Eli Lilly’s Kisunla, viewed as a significant Alzheimer’s advancement.
Final out-of-pocket costs will depend on negotiations between drug developers and Chinese insurance companies.